License Agreement/Revenue Recognition (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
Apr. 30, 2014	Jun. 30, 2016
Revenue Recognition [Line Items]
Deferred Revenue		$ 426,000
Vyrix Pharmaceuticals Inc [Member]
Revenue Recognition [Line Items]
Potential Milestone Payments Receivable	$ 3,025,000
Deferred Revenue	$ 250,000
Deferred Revenue Recognition Period	7 years
Agreement Expiration Period	15 years
Ampio [Member]
Revenue Recognition [Line Items]
Potential Milestone Payments Receivable		$ 3,200,000
Percentage Of Royalty Rate Of Net Sales		25.00%
Deferred Revenue		$ 500,000
Proceeds from License Fees Received		$ 418,000
Deferred Revenue Recognition Period		10 years

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant